NCT02349698

A Clinical Research of Chimeric Antigen Receptor (CAR) T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma

Study Summary

The main purpose of this research is to verify the safety of CD19 targeted chimeric antigen receptor T cells and to determine the proper dosage of CAR T cells infused.

Want to learn more about this trial?

Request More Info

Interventions

Chimeric Antigen Receptor Modified T cells Targeting CD19BIOLOGICAL
T cells modified with CD19 targeted chimeric antigen receptor.

Study Locations

FacilityCityStateCountry
Southwest Hospital of Third Millitary Medical UniversityChongqingChongqing MunicipalityChina

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026